share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/11/13 10:27

Moomoo AI 已提取核心訊息

Applied DNA Sciences received a notification from Nasdaq on November 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's stock price remained below this threshold for 31 consecutive business days from September 27 to November 11, 2024.The company has been granted until May 12, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements.In response, Applied DNA Sciences plans to implement a reverse stock split within 30 days of the Stockholder Approval Date, as required by their recent securities offering agreement, unless compliance is regained within that period. This action aims to maintain Nasdaq listing and fulfill obligations under the Purchase Agreement from October 31, 2024.
Applied DNA Sciences received a notification from Nasdaq on November 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's stock price remained below this threshold for 31 consecutive business days from September 27 to November 11, 2024.The company has been granted until May 12, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If unsuccessful, the company may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements.In response, Applied DNA Sciences plans to implement a reverse stock split within 30 days of the Stockholder Approval Date, as required by their recent securities offering agreement, unless compliance is regained within that period. This action aims to maintain Nasdaq listing and fulfill obligations under the Purchase Agreement from October 31, 2024.
Applied DNA Sciences於2024年11月12日收到了納斯達克的通知,表明其未能滿足每股至少$1.00的最低買盤價格要求。該公司的股票價格在2024年9月27日至11月11日期間連續31個交易日低於此門檻。公司被授權在2025年5月12日之前,通過在至少10個連續交易日內維持至少$1.00的收盤買盤價格來恢復合規。如果未能成功,公司可能有資格獲得額外的180天合規期,前提是滿足其他納斯達克資本市場上市要求。作爲回應,Applied DNA Sciences計劃在股東批准日期後的30天內執行反向股票拆分,符合其最近的證券發行協議,除非在此期間恢復合規。此舉旨在維持納斯達克上市並履行2024年10月31日購買協議下的義務。
Applied DNA Sciences於2024年11月12日收到了納斯達克的通知,表明其未能滿足每股至少$1.00的最低買盤價格要求。該公司的股票價格在2024年9月27日至11月11日期間連續31個交易日低於此門檻。公司被授權在2025年5月12日之前,通過在至少10個連續交易日內維持至少$1.00的收盤買盤價格來恢復合規。如果未能成功,公司可能有資格獲得額外的180天合規期,前提是滿足其他納斯達克資本市場上市要求。作爲回應,Applied DNA Sciences計劃在股東批准日期後的30天內執行反向股票拆分,符合其最近的證券發行協議,除非在此期間恢復合規。此舉旨在維持納斯達克上市並履行2024年10月31日購買協議下的義務。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息